Free tool
FAERS Monitor: Ethamolin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019357 or its brand name (Ethamolin, Ethanolamine Oleate). Reports on generic versions are filed under their own applications.
Reports
18
Serious
18
100% of reports
Hospitalization
1
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- oesophageal varices haemorrhage5
- portal vein thrombosis3
- product use in unapproved indication3
- off label use2
- abdominal pain1
- abdominal pain upper1
- anaemia1
- arterial haemorrhage1
- ascites1
- cataract1
- disseminated intravascular coagulation1
- dry eye1
- essential thrombocythaemia1
- gastrointestinal ischaemia1
- haemorrhagic ascites1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 8 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastrointestinal ischaemia | 1 | 4238.0 | 628.5 | 1,055 |
| haemorrhagic ascites | 1 | 4104.1 | 608.8 | 1,021 |
| essential thrombocythaemia | 1 | 3178.5 | 471.8 | 791 |
| oesophageal varices haemorrhageSignal | 5 | 2697.6 | 1279.2 | 10,892 |
| portal vein thrombosisSignal | 3 | 1086.0 | 386.3 | 2,256 |
| arterial haemorrhage | 1 | 1024.2 | 152.3 | 255 |
| disseminated intravascular coagulation | 1 | 83.0 | 12.4 | 20 |
| ascites | 1 | 39.7 | 5.9 | 9 |
| dry eye | 1 | 23.4 | 3.5 | 5 |
| cataract | 1 | 19.6 | 2.9 | 4 |
| product use in unapproved indicationSignal | 3 | 14.1 | 5.0 | 25 |
| anaemia | 1 | 6.1 | 0.9 | 1 |
| abdominal pain upper | 1 | 5.7 | 0.8 | 1 |
| abdominal pain | 1 | 5.0 | 0.7 | 0 |
| off label use | 2 | 2.7 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.